Annual Report

The report presents FY25 as a year of stronger consolidated performance, sustainability progress, and more developed ESG governance. It reports energy-efficiency, GHG, and water-intensity improvements, renewable-energy expansion, and ESG disclosures aligned with BRSR and GRI. Consolidated revenue from operations reached ₹72,345 million, while the Generics business returned to profitability and the CDMO Sterile Injectables business continued capacity expansion.